Infanrix hexa is a vaccine used to protect infants from six weeks of age and toddlers against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio) and diseases such as bacterial meningitis caused by the bacterium Haemophilus influenzae type b (Hib). Infanrix hexa contains the following active substances: - toxoids (chemically weakened toxins) from diphtheria and tetanus; - parts of Bordetella pertussis (pertussis, a bacterium that causes whooping cough); - parts of the hepatitis B virus; - inactivated polioviruses; - polysaccharides (sugars) from Hib.
Therapeutic Indication
### Therapeutic indication Infanrix hexa is indicated for primary and booster vaccination of infants from the age of 6 weeks and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b. The use of Infanrix hexa should be in accordance with official recommendations.
Therapeutic Area (MeSH)
ATC Code
J07CA09
ATC Item
diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B
Pharmacotherapeutic Group
Vaccines
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Diphtheria toxoid | N/A | 白喉类毒素 |
| tetanus toxoid | N/A | 破伤风类毒素 |
| hepatitis B surface antigen | N/A | 乙型肝炎病毒表面抗原 |
| poliovirus (inactivated) (type-1 (Mahoney strain), type-2 (MEF-1 strain), type-3 (Saukett strain)) | N/A | inactivated poliovirus vaccine |
| Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin) | N/A | Bordetella pertussis pertactin antigen |
| Haemophilus influenzae type b polysaccharide | N/A | haemophilus influenzae type b |
EMA Name
Infanrix Hexa
Medicine Name
Infanrix Hexa
Aliases
N/ANo risk management plan link.
